A spotlight on tomorrow’s CRO

As an integral part of the drug development journey, the CRO market is in a period of exponential growth. A symptom of a drug and medical device industry in acceleration mode, an influx of innovation and much-awaited medicines are just around the corner. In addition, trials are getting more complex and require an increasing level of expertise.

With new logistical challenges, market growth and opportunity come new CRO players and established brands hoping to broaden their scope. The pandemic was a double-edged sword for the industry as it demanded increased flexibility and reliance on technology.

Flexibility is paramount
Clients of 2022 and beyond are not looking for a one-trial-fits-all way of working. With protocol complexity and project sizes varying wildly from trial to trial, sponsors are not looking for a one-size-fits-all cookie-cutter service. Instead, a CRO that offers flexibility, (both in terms of service delivery, patient recruitment strategies and technology solutions) will meet the needs of the sponsor of tomorrow.

As a mid-sized CRO headquartered in Europe, Excelya is unique in its ability to provide full spectrum CRO ser-vices across three business models:  Full Service, FSP and Outsourcing.

Operating on a fully flexible basis, with deep therapeutic expertise and understanding of the nuanced needs of clients, Excelya offers services that suit any budget, and can be ramped up quickly to respond to the needs of our partners. We deliver proven tailor-made solutions to biotechs and pharmaceutical brands alike. Our services enable sponsors to tap into a deep resource of expertise and talent to ensure a trial’s success.

Delivering excellence
Despite having been founded in 2014, Excelya has quickly grown to over 900 staff worldwide. Built on a wealth of highly specific expertise and long-standing partnerships, our operational and medical teams have decades of experience and, by proxy, many of our clients have been working with us and our subsidiaries for more than ten years.

Right-sized
As a medium-sized CRO, at Excelya we have an impressive knowledge and re-source base, an extensive operational know-how and an agile, flexible and responsive way of working that is precisely aligned with customer needs, rising to the challenges of each individual trial. There is also a strong focus on sustain-ability – we scored highly in and achieved a silver EcoVadis rating last year. We have a global footprint, providing scale and reach to patients and sites, with strong local relationships and teams maintaining a human touch. For more information about how Excelya can help you realise your clinical trials goals and accelerate your drug or medical device approval, please email contact@excelya.com.

This article was originally published in European Biotechnology Magazine Autumn Edition 2022.